MECOM and acute myeloid leukemia: The selective BRG1/BRM inhibitor FHD-286 has been shown to reduce EVI1 protein levels, and when combined with decitabine, BETi (OTX015), or HAT inhibitor (GNE-781), exerted synergistic antileukemic effects in MECOM-rearranged AML cells [69].